SCHEMBL4674101

SCHEMBL4674101

O=C(C=C(O)c1nc[nH]n1)c1ccn(S(=O)(=O)c2ccc(Cl)cc2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.38
AKR1C1 Q04828 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
CNKSR1 Q969H4 1/20 0.33
PKM P14618 5/20 0.33
MAPT P10636 1/20 0.33
GRM4 Q14833 1/20 0.32
LMNA P02545 2/20 0.32
ALDH1A1 P00352 4/20 0.31
PSEN1 P49768 2/20 0.31
PSEN2 P49810 2/20 0.31
APH1B Q8WW43 2/20 0.31
NCSTN Q92542 2/20 0.31
APH1A Q96BI3 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671111 0.90 AKR1C3 (0.38) AKR1C3AKR1C1SMN1; SMN2MEN1CYP3A4
SCHEMBL4679719 0.83 AKR1C3 (0.38) AKR1C3AKR1C1SMN1; SMN2MEN1CYP3A4
SCHEMBL4677715 0.80 GRM4 (0.33) AKR1C3SMN1; SMN2MEN1KMT2APKM
SCHEMBL4676937 0.79 RAPGEF4 (0.39) SMN1; SMN2PKMGRM4LMNAALDH1A1
SCHEMBL4671386 0.79 ALDH1A1 (0.51) SMN1; SMN2MEN1KMT2APKMGRM4
SCHEMBL4675007 0.79 AKR1C3 (0.44) AKR1C3AKR1C1SMN1; SMN2MEN1CYP3A4
SCHEMBL4673637 0.77 ALDH1A1 (0.41) AKR1C3SMN1; SMN2MEN1CYP3A4CYP2C9
SCHEMBL4678210 0.75 CA2 (0.34) AKR1C3PKMLMNAALDH1A1PSEN1
SCHEMBL4675909 0.75 CA2 (0.34) PKMLMNAALDH1A1PSEN1PSEN2
SCHEMBL4672762 0.74 NPC1 (0.31) CYP3A4MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1C3 30/4885AKR1C1 25/4885SMN1; SMN2 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.